Sydney, February 16, 2026, 17:01 AEDT — The session has ended.
- CSL shares finished 1.4% higher after the company announced Australian approval for its neffy adrenaline nasal spray.
- CSL continued its share buybacks, the update showed, picking up more stock after last week’s steep drop.
CSL Ltd picked up 1.4% by Monday’s close, recouping a slice of last week’s drop. The move followed news that its Seqirus arm secured Australian approval for the neffy adrenaline nasal spray, alongside a fresh update on the company’s share buyback. Shares wrapped up at A$152.17, though that’s still roughly 15.6% below where they stood five sessions ago. 1
CSL’s stock has been struggling, and investors have been eager for real signals — think products, cost discipline, or capital returns — that might stabilize the mood. Monday saw a small uptick, this time on the back of new, company-focused news rather than the usual market chatter.
CSL Seqirus announced that its neffy (adrenaline/epinephrine) nasal spray has secured approval in Australia for emergency use in anaphylaxis cases—covering both adults and children four and up, as long as they weigh at least 15 kg. Professor Connie Katelaris, an allergist from NSW, described the approval as “very welcome,” noting this is the country’s first new adrenaline administration method to get the green light in over three decades. Maria Said from Allergy & Anaphylaxis Australia pointed out that a non-injectable option gives patients and doctors more flexibility when picking a device. CSL Seqirus executive medical director Dr Jonathan Anderson confirmed that CSL has filed for Pharmaceutical Benefits Scheme inclusion, with a decision expected in March 2026. 2
CSL kept up its on-market buyback, snapping up 126,464 shares during the previous session for about A$19.2 million, according to a new filing. Shares traded between A$150.01 and A$156.11 for the day. The company plans to run the buyback through June 30, 2026, targeting up to US$750 million, with UBS Securities Australia as the broker. 3
With an on-market buyback, the company steps in to purchase its own shares directly on the stock exchange. Fewer shares in circulation can lift earnings per share. Management might be flagging confidence in the current valuation, but that doesn’t guarantee a price floor.
Even so, just how neffy will perform commercially in the short run remains uncertain. Prescriptions, what patients want, and reimbursement will play a role. The PBS process itself is often drawn out and unpredictable.
March is the key date on the calendar—CSL flagged that’s when its PBS submission for neffy heads for review. Investors are eyeing that decision, looking for any signals on both pricing and access, as well as additional details on the company’s buyback plans. 2
